# Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

> **NCT02588092** · PHASE1 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 35 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** ADCT-301

## Key facts

- **NCT ID:** NCT02588092
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-01
- **Primary completion:** 2018-08-29
- **Final completion:** 2018-08-29
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588092, "Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02588092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*